Factor IXa inhibitors
View Patent ↗The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
1. A compound of Formula (I)
wherein
R 1 is
1) an aryl ring, or
2) a heteroaryl ring, wherein the point of attachment to the heteroaryl ring is a carbon atom, and the heteroaryl ring is selected from the group consisting of:
a) a 5- or 6-membered unsaturated monocyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,
b) an 9- or 10-membered unsaturated bicyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,
said aryl and heteroaryl ring is unsubstituted, or independently mono-, di-, or tri-substituted with R 7 ;
R 5 is
1) an aryl ring, or
2) a heteroaryl ring, wherein the point of attachment to the heteroaryl ring is a carbon atom, and the heteroaryl ring is selected from the group consisting of:
a) a 5- or 6-membered unsaturated monocyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,
b) an 9- or 10-membered unsaturated bicyclic ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S,
said aryl and heteroaryl ring is unsubstituted, or independently mono-, di-, or tri-substituted with R 9 ;
R 7 , each time in which it occurs, is independently —C(═NR 11 )N(R 11 ) 2 , —N(R 11 ) 2 , —CN or —C 1-6 alkyl;
R 9 , each time in which it occurs, is independently —OCF 3 , halogen, —C(O)R 10 , —C 1-6 alkyl, —N(R 12 ) 2 , —CF 3 , R 10 or OR 10 ;
R 10 is a 6-membered heterocycle ring containing 1 or 2 heteroatoms independently selected from O and N, which is unsubstituted or substituted with ═O;
R 11 , each time in which it occurs, is independently hydrogen or —C 1-6 alkyl; and
R 12 , each time in which it occurs, is independently hydrogen or —C 1-6 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is —NH 2 .
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 9 , each time in which it occurs, is independently —OCF 3 , F, —C(O)R 10 , —C(CH 3 ) 3 , R 10 or OR 10 .
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is a 9- or 10-membered unsaturated bicyclic heteroaryl ring with 1, 2, 3, or 4 heteroatom ring atoms selected from the group consisting of N, O or S, wherein said heteroaryl ring is unsubstituted, or independently mono-, di-, or tri-substituted with R 9 .
5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is
6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 1 is
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is aryl, wherein said phenyl ring is unsubstituted, or independently mono-, di-, or tri-substituted with R 9 .
8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein R 5 is phenyl, wherein said phenyl ring is unsubstituted, or independently mono-, di-, or tri-substituted with R 9 .
9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 5 is
10. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 5 is
11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein R 5 is
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 9 is —OCF 3 , —C(CH 3 ) 3 ,
13. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
N-(3-aminobenzo[d]isoxazol-6-yl)-2-(1-(4-fluoro-3-(tetrahydro-2H-pyran-4-yloxy)phenyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxyacetamide,
(±)-N-(3-aminobenzo[d]isoxazol-6-yl)-2-hydroxy-2-(2-oxo-1-(4-(trifluoromethoxy)phenyl)-1,2-dihydropyridin-3-yl)acetamide,
(±)-N-(3-aminobenzo[d]isoxazol-6-yl)-2-hydroxy-2-(2-oxo-1-(3-(3-oxomorpholino)phenyl)-1,2-dihydropyridin-3-yl)acetamide,
N-(8-amino-2,7-naphthyridin-3-yl)-2-hydroxy-2-(2-oxo-1-(4-(trifluoromethoxy)phenyl)-1,2-dihydropyridin-3-yl)acetamide,
(±)-N-(3-aminobenzo[c/]isoxazol-6-yl)-2-(1-(4-tert-butylphenyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxyacetamide, or
(±)-N-(1-aminoisoquinolin-6-yl)-2-(1-(4-tert-butylphenyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxyacetamide.
14. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent selected from the group consisting of anticoagulants, anti-thrombin agents, anti-platelet agents, fibrinolytics, hypolipidemic agents, antihypertensive agents, and anti-ischemic agents.
16. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and an effective amount of at least one agent selected from the group consisting of warfarin, heparin, aprotinin, a synthetic pentasaccharide, a boroarginine derivative, a boropeptide, heparin, hirudin, argatroban, a thromboxane-A2-receptor antagonist, a thromboxane-A2-synthetase inhibitor, a PDE-III inhibitor, a PDE V inhibitor, a ADP receptor antagonist, an antagonist of the purinergic receptor P2Y1, an antagonist of the purinergic receptor P2Y12, tissue plasminogen activator and modified forms thereof, anistreplase, urokinase, streptokinase, tenecteplase, lanoteplase, a PAI-I inhibitor, an alpha-2-antiplasmin inhibitor, an anisoylated plasminogen streptokinase activator complex, a HMG-CoA reductase inhibitor, a squalene synthetase inhibitor, a fibrate, a bile acid sequestrant, an ACAT inhibitor, a MTP inhibitor, a lipooxygenase inhibitor, a cholesterol absorption inhibitor, a cholesterol ester transfer protein inhibitor, an alpha adrenergic blocker, a beta adrenergic blocker, a calcium channel blocker, a diuretic, a renin inhibitor, an angiotensin-converting enzyme inhibitor, an angiotensin-II-receptor antagnonist, an ET receptor antagonist, a Dual ET/All antagonist, a neutral endopeptidase inhibitor, a vasopepsidase inhibitor, a Class I agent, a Class II agent, a Class III agent, a Class IV agent, an IAch inhibitor, an IKur inhibitor and a cardiac glycoside.